Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

Authors

ANTUNES Liliana MAZAGATOS Clara MARTÍNEZ-BAZ Iván NAESENS Reinout BORG Maria-Luise PETROVIC Goranka FATUKASI Terra JANCORIENE Ligita MACHADO Ausenda OROSZI Beatrix HUSA Petr LAZAR Mihaela DÜRRWALD Ralf HOWARD Jennifer MELO Aryse PÉREZ-GIMENO Gloria CASTILLA Jesús BERNAERT Eva DŽIUGYTÉ Aušra LOVRIC MAKARIC Zvjezdana FITZGERALD Margaret MICKIENÉ Auksé GOMEZ Veronica TÚRI Gergö SOUČKOVÁ Lenka MARIN Alexandru TOLKSDORF Kristin NICOLAY Nathalie ROSE Angela MC

Year of publication 2024
Type Article in Periodical
Magazine / Source Influenza and Other Respiratory Viruses
MU Faculty or unit

Faculty of Medicine

Citation
Web https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13360?src=getftr
Doi http://dx.doi.org/10.1111./irv.13360
Keywords COVID-19 XBB1.5 vaccine; Europe; SARS-CoV- 2 hospitalisation; vaccine effectiveness
Description We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 amongadult patients aged ? 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of theeffectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS- CoV-2 hospitalisation. Vaccineeffectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, withVE > 70% in older adults (? 65 years) up to 1 month post vaccination.

You are running an old browser version. We recommend updating your browser to its latest version.

More info